Yourgene Health

Premaitha is an international molecular diagnostics group which utilize the DNA analysis technology to develop and regulatory approved genetic screening tests. Co.'s primary focus is on non-invasive prenatal tests (NIPT) for pregnant women. Co.'s NIPT solutions include: regulated in vitro diagnostic product supply that enable clinical laboratories to establish their quality assured, regulated, NIPT analysis offering; clinical laboratory service, which available in Manchester, the U.K. and Taipei, Taiwan, where customers can send blood samples for NIPT analysis; and portfolio of technology, which has developed to support laboratories and healthcare to generate the NIPT analysis.
  • TickerYGEN
  • ISINGB00BN31ZD89
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

MarketLine Department

ValiRx Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's ValiRx Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by ValiRx Plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights T...

Brian Moretta ...
  • Dorothea Hill
  • Doug Hawkins
  • Mark Thomas
  • Martin Hall
  • Mike Foster
  • Nigel Hawkins
  • Paul Singer
  • Stephen Clapham
  • Thomas Wigglesworth
  • Tony Williams
  • Yingheng Chen

Hardman & Co Monthly: March 2018

In the March 2018 edition of the Hardman Monthly Newsletter, Nigel Hawkins addresses the attractions of quoted infrastructure funds that maintain a low profile. Over the next decade, infrastructure investment levels will remain high, especially in the energy, utilities and railways sectors. As such, infrastructure funds are well-placed to benefit from this trend. These funds, three of which are valued by the market at over £2bn, have been resilient performers over the last five years, although there has been some share price weakness of late. By contrast, utility stocks have suffered on th...

Feasibility Study Results in